COAG Stock Forecast: Hemab Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$39
−1.43% on the day

The 7 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. hold a median 12-month price target of $64 — +62.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 2 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
2/ 100
Median analyst target
$64
Analysts covering
7
Revenue$0.0
Operating income−$26.1M
Net income−$24.1M
Free cash flow−$22.7M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
+15.0%
From high
−28.5%
From low
+57.3%
$25
$55
Range since 1 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Hemab Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
2/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
29
Value
23
Momentum
20
Issuance
14
Growth
10
Quality
5
Accruals
5
Volatility
4

Revisions (29): Analysts have, on balance, been raising their forecasts.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

COAG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COAG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 1 May 2026Adjusted close, US dollars
$20$30$40$50$60$70May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COAGHigh $70Median $64Low $54

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7
Buy
0
Hold
0
Sell
$54
Low
$64
Median
$70
High

The green dot is the last close — the median target sits +62.9% from it.

Recent analyst actionsNewest first

Of the 14 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
9 Nov 2026LifeSci CapitalInitiatesOutperform$65
15 Oct 2026JP MorganInitiatesOverweight$70
12 Oct 2026Rodman & RenshawInitiatesBuy$56
12 Aug 2026WedbushMaintainsOutperform$55 → $64
11 Aug 2026HC Wainwright & Co.MaintainsBuy$52 → $60
13 July 2026HC Wainwright & Co.MaintainsBuy$40 → $52
13 July 2026JefferiesMaintainsBuy$39 → $47
13 July 2026WedbushMaintainsOutperform$42 → $55
26 June 2026HC Wainwright & Co.ReiteratesBuy—
17 June 2026HC Wainwright & Co.InitiatesBuy—
26 May 2026Evercore ISI GroupInitiatesOutperform—
26 May 2026Goldman SachsInitiatesBuy—
26 May 2026JefferiesInitiatesBuy—
26 May 2026WedbushInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for COAG.

Market Radar

This page is one stock. Monday covers all of them.

COAG appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

COAG vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

COAG vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COAGS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

COAG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
4.3×

Cheaper than 22% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−32.8%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Hemab Therapeutics Holdings, Inc. has a market value of $1.8B and an enterprise value of $1.4B.

  • Shares outstanding: 46.7M.

  • Hemab Therapeutics Holdings, Inc. employs 59 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

COAG and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
COAGHemab Therapeutics Holdings, Inc.$1.8B2
SEPNSepterna, Inc.$1.8B54
IMNMImmunome, Inc.$1.9B21
MRVIMaravai Lifesciences Holdings, Inc.$1.8B94
ZYMEZymeworks, Inc.$1.9B83
BHVNBiohaven Ltd.$1.8B53
REPLReplimune Group, Inc.$1.8B63

Take a look at COAG’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Hemab Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about COAG

What is the COAG stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Hemab Therapeutics Holdings, Inc. have a median 12-month price target of $64, with estimates ranging from $54 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COAG stock a buy right now?

Of the 7 analysts covering Hemab Therapeutics Holdings, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hemab Therapeutics Holdings, Inc. 2 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COAG?

As at 21 Nov 2026, Hemab Therapeutics Holdings, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (29 of 100).

Will COAG stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +62.9% from the last close, and Ticker Nerd's factor model ranks Hemab Therapeutics Holdings, Inc. 2 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COAG stock forecast for 2030?

No analyst covering Hemab Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COAG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $54 to $70 over the next 12 months.

What does Hemab Therapeutics Holdings, Inc. do?

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Hemab Therapeutics Holdings, Inc. is advancing a pipeline of treatments designed to address serious inherited bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease.

Company

About Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Hemab Therapeutics Holdings, Inc. is advancing a pipeline of treatments designed to address serious inherited bleeding conditions, including Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its lead programs include sutacimig (HMB-001), a bispecific antibody, and HMB-002, a monovalent antibody, both being studied in clinical development for prophylactic use. The company’s work centers on bleeding and coagulation biology, with an emphasis on therapeutic approaches that target underlying disease mechanisms rather than symptom management. Hemab Therapeutics Holdings, Inc. operates as a research-driven biotechnology business serving the rare disease and hematology markets.

CEO Dr. Benny Sorensen M.D., Ph.D. · 59 employees · United States · https://www.hemab.com